{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:51Z","timestamp":1792783491255,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Personnel Training and Promotion Program of Xijing Hospital","award":["XJZT24QN41"],"award-info":[{"award-number":["XJZT24QN41"]}],"id":[{"id":"https:\/\/ror.org\/05cqe9350","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370588"],"award-info":[{"award-number":["82370588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Shaanxi Province, Key Industrial Innovation Project Fund","award":["2023-ZDLSF-44"],"award-info":[{"award-number":["2023-ZDLSF-44"]}]},{"name":"National Natural Science Foundation of China Major Research Program Integration Project","award":["92259302"],"award-info":[{"award-number":["92259302"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Independent Funds of the Key Laboratory","award":["CBSKL2022ZZ34"],"award-info":[{"award-number":["CBSKL2022ZZ34"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01731-x","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T02:47:33Z","timestamp":1753066053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual-targeted therapy for the management of refractory Crohn\u2019s disease: a retrospective cohort study"],"prefix":"10.1007","volume":"25","author":[{"given":"Jindan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"10432","key":"1731_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/s0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403(10432):1177\u201391. https:\/\/doi.org\/10.1016\/s0140-6736(23)02586-2.","journal-title":"Lancet"},{"issue":"11","key":"1731_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103655","volume":"23","author":"Z Dou","year":"2024","unstructured":"Dou Z, Zheng H, Shi Y, Li Y, Jia J. Analysis of global prevalence, DALY and trends of inflammatory bowel disease and their correlations with sociodemographic index: data from 1990 to 2019. Autoimmun Rev. 2024;23(11): 103655. https:\/\/doi.org\/10.1016\/j.autrev.2024.103655.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1731_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.042.","journal-title":"Gastroenterology"},{"key":"1731_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091185","author":"A di Rienzo","year":"2024","unstructured":"di Rienzo A, Marinelli L, Dimmito MP, Toto EC, Di Stefano A, Cacciatore I. Advancements in inflammatory bowel disease management from: traditional treatments to monoclonal antibodies and future drug delivery systems. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16091185.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1731_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","volume":"16","author":"M Duijvestein","year":"2018","unstructured":"Duijvestein M, Battat R, Vande Casteele N, et al. Novel therapies and treatment strategies for patients with inflammatory bowel disease. Curr Treat Options Gastroenterol. 2018;16(1):129\u201346. https:\/\/doi.org\/10.1007\/s11938-018-0175-1.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"12","key":"1731_CR6","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","volume":"25","author":"DR Berg","year":"2019","unstructured":"Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896\u2013905. https:\/\/doi.org\/10.1093\/ibd\/izz059.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"1731_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","volume":"16","author":"RP Hirten","year":"2018","unstructured":"Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JF. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol. 2018;16(9):1374\u201384. https:\/\/doi.org\/10.1016\/j.cgh.2018.02.024.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1731_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","volume":"231","author":"O Bernell","year":"2000","unstructured":"Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn\u2019s disease. Ann Surg. 2000;231(1):38\u201345. https:\/\/doi.org\/10.1097\/00000658-200001000-00006.","journal-title":"Ann Surg"},{"issue":"1","key":"1731_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000527422","volume":"104","author":"M Higashiyama","year":"2023","unstructured":"Higashiyama M, Hokari R. New and emerging treatments for inflammatory bowel disease. Digestion. 2023;104(1):74\u201381. https:\/\/doi.org\/10.1159\/000527422.","journal-title":"Digestion"},{"issue":"9","key":"1731_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s2468-1253(23)00154-1","volume":"8","author":"TL Parigi","year":"2023","unstructured":"Parigi TL, D\u2019Amico F, Abreu MT, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023;8(9):853\u20139. https:\/\/doi.org\/10.1016\/s2468-1253(23)00154-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"1731_CR11","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","volume":"71","author":"S Danese","year":"2022","unstructured":"Danese S, Solitano V, Jairath V, Peyrin-Biroulet L. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022;71(12):2380\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2022-327025.","journal-title":"Gut"},{"issue":"1","key":"1731_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ibd.20014","volume":"13","author":"BE Sands","year":"2007","unstructured":"Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13(1):2\u201311. https:\/\/doi.org\/10.1002\/ibd.20014.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1731_CR13","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361\u201379. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"1731_CR14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3748\/wjg.v30.i15.2068","volume":"30","author":"JK Triantafillidis","year":"2024","unstructured":"Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol. 2024;30(15):2068\u201380. https:\/\/doi.org\/10.3748\/wjg.v30.i15.2068.","journal-title":"World J Gastroenterol"},{"key":"1731_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114174","volume":"158","author":"Z Feng","year":"2023","unstructured":"Feng Z, Kang G, Wang J, et al. Breaking through the therapeutic ceiling of inflammatory bowel disease: dual-targeted therapies. Biomed Pharmacother. 2023;158: 114174. https:\/\/doi.org\/10.1016\/j.biopha.2022.114174.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1731_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut. 2019;68(5):814\u201328. https:\/\/doi.org\/10.1136\/gutjnl-2017-315671.","journal-title":"Gut"},{"issue":"1","key":"1731_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","volume":"67","author":"Y Bouhnik","year":"2018","unstructured":"Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn\u2019s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67(1):53\u201360. https:\/\/doi.org\/10.1136\/gutjnl-2016-312581.","journal-title":"Gut"},{"issue":"5","key":"1731_CR18","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s10787-024-01508-w","volume":"32","author":"ME Kamal","year":"2024","unstructured":"Kamal ME, Werida RH, Radwan MA, et al. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology. 2024;32(5):3259\u201369. https:\/\/doi.org\/10.1007\/s10787-024-01508-w.","journal-title":"Inflammopharmacology"},{"key":"1731_CR19","unstructured":"Inflammatory Bowel Disease Study Group of Chinese Society of Gastroenterology, Chinese Inflammatory Bowel Disease Diagnosis and Treatment Quality Control and Evaluation Center. Chinese guidelines for the diagnosis and treatment of Crohn\u2019s Disease (2023\u00b7Guangzhou). Chinese J Inflamm Bowel Dis (in English and Chinese). 2024;(1):2\u201332."},{"issue":"4","key":"1731_CR20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505\u201312. https:\/\/doi.org\/10.1016\/s0016-5107(04)01878-4.","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"1731_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn\u2019s disease activity index national cooperative Crohn\u2019s disease study. Gastroenterology. 1976;70(3):439\u201344.","journal-title":"Gastroenterology"},{"issue":"6","key":"1731_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","volume":"42","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase II\/III clinical development programs. Drug Saf. 2019;42(6):751\u201368. https:\/\/doi.org\/10.1007\/s40264-019-00797-3.","journal-title":"Drug Saf"},{"issue":"3","key":"1731_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of Ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-590.e4. https:\/\/doi.org\/10.1016\/j.cgh.2021.02.025.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10342","key":"1731_CR24","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/s0140-6736(22)00688-2","volume":"399","author":"BE Sands","year":"2022","unstructured":"Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200\u201311. https:\/\/doi.org\/10.1016\/s0140-6736(22)00688-2.","journal-title":"Lancet"},{"issue":"8","key":"1731_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739.","journal-title":"N Engl J Med"},{"issue":"9","key":"1731_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","volume":"53","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048\u201364. https:\/\/doi.org\/10.1007\/s00535-018-1480-0.","journal-title":"J Gastroenterol"},{"issue":"11","key":"1731_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/apt.15719","volume":"51","author":"E Yang","year":"2020","unstructured":"Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;51(11):1031\u20138. https:\/\/doi.org\/10.1111\/apt.15719.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1731_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102832","volume":"20","author":"G Privitera","year":"2021","unstructured":"Privitera G, Pugliese D, Onali S, et al. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev. 2021;20(6): 102832. https:\/\/doi.org\/10.1016\/j.autrev.2021.102832.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1731_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1053\/j.gastro.2021.04.068","volume":"161","author":"C Stalgis","year":"2021","unstructured":"Stalgis C, Deepak P, Mehandru S, Colombel JF. Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease. Gastroenterology. 2021;161(2):394\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.068.","journal-title":"Gastroenterology"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01731-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01731-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:52Z","timestamp":1764917212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01731-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01731-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6199348\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors confirmed no conflicts of interest statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted following the guidelines of the Declaration of Helsinki and proved by the Medical Ethics Committee of the First Affiliated Hospital of the Air Force Medical University (reference number: KY20222333-C-1). Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"257"}}